IL-15

IL-15 詳細

英語名Interleukin-15市販薬剤の数0
治験薬の数27ターゲットの別称IL-15,Interleukin-15,IL15,Interleukin 15,MGC9721
研究&開発段階Phase 2 Clinical
英語名Interleukin-15
ターゲットの別称IL-15,Interleukin-15,IL15,Interleukin 15,MGC9721
市販薬剤の数0
治験薬の数27
研究&開発段階Phase 2 Clinical

IL-15 製品リスト

  • 属性

    Protein (14)Antibody (3)Kits (2)

  • 製品ライブラリ

    オンライン (18)研究中 (1)

  • Human (12)Mouse (6)Cynomolgus / Rhesus macaque (1)

  • タグ

    Tag Free (6)Fc Tag & Avi Tag (2)Fc Tag (2)His Tag (3)His Tag & Avi Tag (1)- (5)

  • マーカー

    Unconjugated (13)Biotin-labeled (3)- (2)PE Labeled (1)

IL-15バックグランド

Interleukin 15 is also known as IL15, IL-15, and is a cytokine with structural similarity to IL-2. Like IL-2, IL-15 binds to and signals through the IL-2/IL-15 beta chain (CD122) and the common gamma chain (gamma-C, CD132). IL-15 is secreted by mononuclear phagocytes (and some other cells) following infection by virus(es). This cytokine induces cell proliferation of natural killer cells; cells of the innate immune system whose principal role is to kill virally infected cells. Interleukin 15 (IL-15) regulates T and natural killer (NK) cell activation and proliferation. Survival signals that maintain memory T cells in the absence of antigen are provided by IL-15. This cytokine is also implicated in NK cell development. In rodent lymphocytes, IL-15 prevents apoptosis by inducing an apoptosis inhibitor, BCL2L1/BCL-x(L). IL-15 has been shown to enhance the anti-tumor immunity of CD8+ T cells in pre-clinical models. A phase I clinical trial to evaluate the safety, dosing, and anti-tumor efficacy of IL-15 in patients with metastatic melanoma and renal cell carcinoma (kidney cancer) has begun to enroll patients at the National Institutes of Health.

IL-15分子の別称

IL-15,Interleukin-15,MGC9721

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
EQ-101EQ101; EQ-101; BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01Phase 2 ClinicalBioniz Therapeutics IncAlopecia; Alopecia Areata; Leukemia, Large Granular Lymphocytic; Lymphoma, T-Cell, Cutaneous
詳細
OrdesekimabHuMab-IL15; AMG-714; PRV-015Phase 2 ClinicalAmgen Inc, Genmab A/S, Provention Bio IncArthritis, Rheumatoid; Celiac Disease; Lymphoma, T-Cell; Psoriasis; Vitiligo
詳細
HCW-9218HCW-9218Phase 2 ClinicalHCW Biologics IncOvarian Neoplasms; Pancreatic Neoplasms; Pulmonary Fibrosis; Solid tumours
詳細
VG-201VG-201Phase 2 ClinicalViroGin Biotech LtdCarcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms
詳細
TEV-53408TEV-53408; TEV-‘408; TEV-408Phase 2 ClinicalTeva Pharmaceutical Industries LtdCeliac Disease; Gastrointestinal Diseases; Vitiligo
詳細
SPGL-008SPGL008; SPGL-008Phase 2 ClinicalShenzhen Sciprogen Bio-Pharmaceutical Co LtdNeoplasms; Urinary Bladder Neoplasms
詳細
GIA-632GIA632; GIA-632Phase 2 ClinicalNovartis AgDermatitis, Atopic; Immune System Diseases; Vitiligo
詳細
JMT-108JMT-108; JMT108Phase 2 ClinicalShanghai Jmt-Bio IncCarcinoma, Non-Small-Cell Lung; Melanoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours
詳細
HY-07121HY-07121; HY07121Phase 2 ClinicalSichuan Huiyu Seacross Pharma Technology LtdSolid tumours
詳細
NY-ESO-1 TCR/IL-15 NKPhase 2 ClinicalReplay Holdings LLC, Syena, The University Of Texas MD Anderson Cancer CenterLiposarcoma, Myxoid; Multiple Myeloma; Sarcoma, Synovial
詳細
IL15-transpresenting WT1-targeted Dendritic Cell Vaccine(Antwerp University Hospital)Phase 2 ClinicalAntwerp University HospitalEsophageal Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms
詳細
CAR-5/IL-15-transduced CB-NK cell therapyPhase 2 ClinicalThe University Of Texas MD Anderson Cancer CenterHematologic Neoplasms
詳細
VG-161VG-161Phase 2 ClinicalCnbg-Virogin Biotech (Shanghai) LtdBiliary Tract Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Liver Neoplasms; Neoplasms; Pancreatic Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms
詳細
Efbalropendekin alfaXmAb-24306; RG-6323; RO-7310729; XmAb-306Phase 1 ClinicalXencor IncMultiple Myeloma; Solid tumours
詳細
SIM-0237SIM-0237; SIM-237Phase 1 ClinicalSimcere Pharmaceutical Group LtdSolid tumours; Urinary Bladder Neoplasms
詳細
HY-0007HY-0007Phase 1 ClinicalSichuan Huiyu Pharmaceutical Co LtdCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours
詳細
GTB-5550GTB-5550; B7H3 TriKE™; cam1615B7H3; GTB-5550 TriKE™Phase 1 ClinicalUniversity Of MinnesotaSolid tumours
詳細
CYTO-102CYTO-NK-102; CYTO-102; COH06Phase 1 ClinicalCytoImmune Therapeutics IncCarcinoma, Non-Small-Cell Lung; Lung Neoplasms
詳細
HCW-9206HCW-9206Phase 1 ClinicalHCW Biologics IncLeukemia, Myeloid, Acute; Solid tumours
詳細
VG-203VG-203; VG2062; VG-2062Phase 1 ClinicalFenojian Biotechnology (Nantong) Co Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, ViroGin Biotech LtdBreast Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Solid tumours
詳細
ARS-15Phase 1 ClinicalARScience Biotherapeutics IncSolid tumours
詳細
IBI-3013IBI3013; IBI-3013Phase 1 ClinicalInnovent Biologics IncAlopecia Areata; Vitiligo
詳細
GTB-3650GTB-3650; GTB-360; OXS-3350; OXS-C3550Phase 1 ClinicalMasonic Cancer Center, University Of MinnesotaBone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
BGB-R046BGBR046; BGB-R046Phase 1 ClinicalBeigene Guangzhou Biologics Manufacturing Co LtdNeoplasm Metastasis; Solid tumours
詳細
RC-198RC-198Phase 1 ClinicalCarcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
詳細
QLF-32004QLF32004; QLF-32004Phase 1 ClinicalQilu Pharmaceutical Co LtdNeoplasms; Solid tumours
詳細
CALY-002CALY-002Phase 1 ClinicalIdd BiotechCeliac Disease; Eosinophilic Esophagitis
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8